In:
Obesity Surgery, Springer Science and Business Media LLC, Vol. 31, No. 3 ( 2021-03), p. 980-986
Kurzfassung:
Bariatric surgery is no longer considered only as a weight loss surgery but also a way of treating obesity-related comorbidities such as type 2 diabetes mellitus (T2DM). Short-term T2DM remissions in patients undergoing laparoscopic sleeve gastrectomy (LSG) have been shown, but there are very few reports on the mid-term results. We aimed to assess the remission rate of T2DM in obese patients after LSG throughout 5-year follow-up. Materials and Methodology We performed a retrospective multicenter cohort analysis of 240 patients who underwent LSG. We assessed the remission rate of T2DM 1 year and 5 years after surgery. Results Forty-six percent of patients achieved T2DM remission 5 years after LSG. The remission group had better weight loss results (median% of total weight loss 5 years after: 30.1% (22.9–37.0) vs 23.0% (13.7–30.2), p 〈 0.001) and were significantly younger than the no remission group (43 (38–52) vs 52 (44–58) years, p 〈 0.001). Duration of T2DM was significantly shorter (2 (1–5) vs 5 (3–10) years, p 〈 0.001) with less insulin requirement and less diabetes-related complications (7.2% vs 19.8%, p 〈 0.001) and significantly lower median DiaRem score (4.0 (IQR 2.0–6.0) vs 12.0 (IQR 5.0–16.0), p 〈 0.001). Preoperative body mass index (BMI) had no effect on remission. Conclusions Our study suggests that diabetes remission after laparoscopic sleeve gastrectomy occurs frequently, and in the 5-year follow-up, it may remain at the level of 46%. We identified the age of patients, duration, and severity of T2DM as factors affecting mid-term diabetes remission. Nevertheless, further well-designed trials are needed to support our findings.
Materialart:
Online-Ressource
ISSN:
0960-8923
,
1708-0428
DOI:
10.1007/s11695-020-05088-w
Sprache:
Englisch
Verlag:
Springer Science and Business Media LLC
Publikationsdatum:
2021
ZDB Id:
2087903-9
